Literature DB >> 22740855

A simplified and modified procedure to culture brain glioma stem cells from clinical specimens.

Bo Qiu1, Dongyong Zhang, Jun Tao, Anhua Wu, Yunjie Wang.   

Abstract

In recent years, the theory of brain glioma stem cells (BGSCs) has facilitated the study of gliomas. BGSCs have been accepted as the origin of gliomas and determine their biological features. Numerous efforts have been made to probe into the biological characteristics and behaviors of BGSCs. However, the culturing of target cells remains the essential first step for research on BGSCs. In this study, we established a simplified procedure to culture and isolate BGSCs from samples of clinical glioma patients. Samples of 17 glioma patients were included in the study, and the processed glioma cells were grown in serum-free stem cell media. After the tumor spheres appeared, a proliferation assay, a single-cell-derived colonies formation assay and an induced differentiation assay were carried out, followed by an immunocytochemistry assay. Serial passage was used to purify the target cells, whereas neither animal experiments nor sorting techniques were included. As a result, CD133(+) BGSCs from 8 out of 17 patients were grown and maintained in a serum-free condition combined with EGF, FGF and B-27 supplements. The tumor sphere cells were serially passaged and showed pluripotency in an induced differentiation assay. Immunocytochemistry identified the committed markers (CD133, GFAP and TU-20) and confirmed the cells were BGSCs and their progeny. The results proved that CD133(+) BGSCs from resected glioma tissue may be cultured in serum-free stem cell media, and may also be purified by conditioned culture combining serial passage, which is time-saving and cost-effective, and allows the cells to be used for subsequent research. The cell sorting techniques and animal experiments of tumorigenecity are optional. Thus, this modified procedure is more practical and feasible than other available procedures.

Entities:  

Year:  2011        PMID: 22740855      PMCID: PMC3362403          DOI: 10.3892/ol.2011.433

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  22 in total

1.  Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells.

Authors:  Michael F Clarke; John E Dick; Peter B Dirks; Connie J Eaves; Catriona H M Jamieson; D Leanne Jones; Jane Visvader; Irving L Weissman; Geoffrey M Wahl
Journal:  Cancer Res       Date:  2006-09-21       Impact factor: 12.701

2.  Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines.

Authors:  Jeongwu Lee; Svetlana Kotliarova; Yuri Kotliarov; Aiguo Li; Qin Su; Nicholas M Donin; Sandra Pastorino; Benjamin W Purow; Neil Christopher; Wei Zhang; John K Park; Howard A Fine
Journal:  Cancer Cell       Date:  2006-05       Impact factor: 31.743

Review 3.  Brain tumor stem cells: new targets for clinical treatments?

Authors:  Patrizia Tunici; Dwain Irvin; Gentao Liu; Xiangpeng Yuan; Zeng Zhaohui; Hiushan Ng; John S Yu
Journal:  Neurosurg Focus       Date:  2006-04-15       Impact factor: 4.047

4.  Isolation of cancer stem cells from adult glioblastoma multiforme.

Authors:  Xiangpeng Yuan; James Curtin; Yizhi Xiong; Gentao Liu; Sebastian Waschsmann-Hogiu; Daniel L Farkas; Keith L Black; John S Yu
Journal:  Oncogene       Date:  2004-12-16       Impact factor: 9.867

5.  Radial glia cells are candidate stem cells of ependymoma.

Authors:  Michael D Taylor; Helen Poppleton; Christine Fuller; Xiaoping Su; Yongxing Liu; Patricia Jensen; Susan Magdaleno; James Dalton; Christopher Calabrese; Julian Board; Tobey Macdonald; Jim Rutka; Abhijit Guha; Amar Gajjar; Tom Curran; Richard J Gilbertson
Journal:  Cancer Cell       Date:  2005-10       Impact factor: 31.743

6.  CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells.

Authors:  Jian Wang; Per Ø Sakariassen; Oleg Tsinkalovsky; Heike Immervoll; Stig Ove Bøe; Agnete Svendsen; Lars Prestegarden; Gro Røsland; Frits Thorsen; Linda Stuhr; Anders Molven; Rolf Bjerkvig; Per Ø Enger
Journal:  Int J Cancer       Date:  2008-02-15       Impact factor: 7.396

7.  Adult glioma incidence trends in the United States, 1977-2000.

Authors:  Kenneth R Hess; Kristine R Broglio; Melissa L Bondy
Journal:  Cancer       Date:  2004-11-15       Impact factor: 6.860

8.  Tumor growth need not be driven by rare cancer stem cells.

Authors:  Priscilla N Kelly; Aleksandar Dakic; Jerry M Adams; Stephen L Nutt; Andreas Strasser
Journal:  Science       Date:  2007-07-20       Impact factor: 47.728

9.  Cancerous stem cells can arise from pediatric brain tumors.

Authors:  Houman D Hemmati; Ichiro Nakano; Jorge A Lazareff; Michael Masterman-Smith; Daniel H Geschwind; Marianne Bronner-Fraser; Harley I Kornblum
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-26       Impact factor: 11.205

10.  Identification of a cancer stem cell in human brain tumors.

Authors:  Sheila K Singh; Ian D Clarke; Mizuhiko Terasaki; Victoria E Bonn; Cynthia Hawkins; Jeremy Squire; Peter B Dirks
Journal:  Cancer Res       Date:  2003-09-15       Impact factor: 12.701

View more
  9 in total

1.  Pygo2 siRNA Inhibit the Growth and Increase Apoptosis of U251 Cell by Suppressing Histone H3K4 Trimethylation.

Authors:  Mingcong Li; Linlin Chao; Jian Wu; Hao Xu; Shanghan Shen; Sifang Chen; Xin Gao; Ning Yu; Zhanxiang Wang
Journal:  J Mol Neurosci       Date:  2015-04-14       Impact factor: 3.444

2.  NVP-BEZ235, a novel dual PI3K/mTOR inhibitor, enhances the radiosensitivity of human glioma stem cells in vitro.

Authors:  Wen-juan Wang; Lin-mei Long; Neng Yang; Qing-qing Zhang; Wen-jun Ji; Jiang-hu Zhao; Zheng-hong Qin; Zhong Wang; Gang Chen; Zhong-qin Liang
Journal:  Acta Pharmacol Sin       Date:  2013-04-22       Impact factor: 6.150

3.  Astrocytoma-associated antigens - IL13Rα2, Fra-1, and EphA2 as potential markers to monitor the status of tumour-derived cell cultures in vitro.

Authors:  Monika Witusik-Perkowska; Magdalena Zakrzewska; Malgorzata Szybka; Wielislaw Papierz; Dariusz J Jaskolski; Pawel P Liberski; Beata Sikorska
Journal:  Cancer Cell Int       Date:  2014-08-22       Impact factor: 5.722

4.  Isolation, cultivation and identification of human lung adenocarcinoma stem cells.

Authors:  DE-Geng Zhang; Ai-Gui Jiang; Hui-Yu Lu; Li-Xin Zhang; Xiao-Yan Gao
Journal:  Oncol Lett       Date:  2014-10-24       Impact factor: 2.967

Review 5.  Research on human glioma stem cells in China.

Authors:  Yao-Dong Zhao; Quan-Bin Zhang; Hua Chen; Xi-Feng Fei; Yun-Tian Shen; Xiao-Yan Ji; Jia-Wei Ma; Ai-Dong Wang; Jun Dong; Qing Lan; Qiang Huang
Journal:  Neural Regen Res       Date:  2017-11       Impact factor: 5.135

6.  Glioblastoma-derived cells in vitro unveil the spectrum of drug resistance capability - comparative study of tumour chemosensitivity in different culture systems.

Authors:  Monika Witusik-Perkowska; Magdalena Zakrzewska; Beata Sikorska; Wielislaw Papierz; Dariusz J Jaskolski; Janusz Szemraj; Pawel P Liberski
Journal:  Biosci Rep       Date:  2017-06-21       Impact factor: 3.840

7.  Artificial microenvironment of in vitro glioblastoma cell cultures changes profile of miRNAs related to tumor drug resistance.

Authors:  Monika Witusik-Perkowska; Magdalena Zakrzewska; Dariusz J Jaskolski; Pawel P Liberski; Janusz Szemraj
Journal:  Onco Targets Ther       Date:  2019-05-20       Impact factor: 4.147

8.  Heterogeneity of circulating epithelial tumour cells from individual patients with respect to expression profiles and clonal growth (sphere formation) in breast cancer.

Authors:  M Pizon; D Zimon; S Carl; U Pachmann; K Pachmann; O Camara
Journal:  Ecancermedicalscience       Date:  2013-08-23

9.  Signal transduction molecule patterns indicating potential glioblastoma therapy approaches.

Authors:  Maria Linda Cruceru; Ana-Maria Enciu; Adrian Claudiu Popa; Radu Albulescu; Monica Neagu; Cristiana Pistol Tanase; Stefan N Constantinescu
Journal:  Onco Targets Ther       Date:  2013-11-29       Impact factor: 4.147

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.